Treace Medical Concepts (TMCI) Stock Price, News & Analysis

Company Overview

Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to surgically correct three planes of the bunion deformity. It also provides Lapiplasty mini-incision system designed to allow the Lapiplasty procedure to be performed through a 3.5cm incision. In addition, the company offers Adductoplasty system designed for reproducible realignment, stabilization, and fusion of the midfoot. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida.

Key Stats

• Today's Range: $5.90 to $7.00
• 50-Day Range: $6.26 to $9.13
• 52-Week Range: $4.29 to $10.79
• Volume: 2.35 million shs
• Average Volume: 680,453 shs
• Market Capitalization: $429.54 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $10.16
• Consensus Rating: Hold

Treace Medical Concepts Stock Analysis - MarketRank™

Treace Medical Concepts scored higher than 52% of companies evaluated by MarketBeat, and ranked 501st out of 913 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.1 / 5
• Analyst Rating: Hold

Consensus Rating

Treace Medical Concepts has received a consensus rating of Hold. The company's average rating score is 2.29, and is based on 2 buy ratings, 5 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Treace Medical Concepts has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Treace Medical Concepts are expected to grow in the coming year, from ($0.92) to ($0.77) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Treace Medical Concepts is -6.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Treace Medical Concepts is -6.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Treace Medical Concepts has a P/B Ratio of 3.05. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

4.97% of the float of Treace Medical Concepts has been sold short.

Short Interest Ratio / Days to Cover

Treace Medical Concepts has a short interest ratio ("days to cover") of 5.5.

Change versus previous month

Short interest in Treace Medical Concepts has recently increased by 3.70%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Treace Medical Concepts does not currently pay a dividend.

Dividend Growth

Treace Medical Concepts does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

4.97% of the float of Treace Medical Concepts has been sold short.

Short Interest Ratio / Days to Cover

Treace Medical Concepts has a short interest ratio ("days to cover") of 5.5.

Change versus previous month

Short interest in Treace Medical Concepts has recently increased by 3.70%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 2.3 / 5
• News Sentiment: 0.12

News Sentiment

Treace Medical Concepts has a news sentiment score of 0.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 36 news articles for Treace Medical Concepts this week, compared to 5 articles on an average week.

Search Interest

2 people have searched for TMCI on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 4.2 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Treace Medical Concepts insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $398,500.00 in company stock.

Percentage Held by Insiders

27.72% of the stock of Treace Medical Concepts is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

84.08% of the stock of Treace Medical Concepts is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

TMCI Stock Analysis - Frequently Asked Questions

How have TMCI shares performed this year?

Treace Medical Concepts' stock was trading at $7.44 at the beginning of 2025. Since then, TMCI shares have decreased by 8.2% and is now trading at $6.83.
View the best growth stocks for 2025 here.

How were Treace Medical Concepts' earnings last quarter?

Treace Medical Concepts, Inc. (NASDAQ:TMCI) posted its quarterly earnings data on Thursday, May, 8th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.06. The firm's quarterly revenue was up 2.9% on a year-over-year basis.
Read the conference call transcript.

When did Treace Medical Concepts IPO?

Treace Medical Concepts (TMCI) raised $150 million in an initial public offering on Friday, April 23rd 2021. The company issued 9,400,000 shares at $15.00-$17.00 per share. J.P. Morgan and Morgan Stanley served as the underwriters for the IPO and SVB Leerink and Stifel were co-managers.

Who are Treace Medical Concepts' major shareholders?

Treace Medical Concepts' top institutional investors include Vanguard Group Inc. (4.30%), Gagnon Securities LLC (2.78%), Deutsche Bank AG (2.04%) and Charles Schwab Investment Management Inc. (0.60%). Insiders that own company stock include John T Treace, John R Treace, James T Treace, Thomas E Timbie, Richard W Mott, Sean F Scanlan, Deepti Jain, Daniel E Owens, Mark Hair, Scot Michael Elder, Aaron Berutti and F Barry Bays.
View institutional ownership trends.

How do I buy shares of Treace Medical Concepts?

Shares of TMCI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Treace Medical Concepts own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Treace Medical Concepts investors own include American Water Works (AWK), DiamondRock Hospitality (DRH), The RMR Group (RMR), Waste Connections (WCN), AUO (AUOTY), iShares Micro-Cap ETF (IWC) and Triple Flag Precious Metals (TFPM).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 5/09/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:TMCI
• CIK: 1630627
• Web: www.treace.com
• Phone: 904-373-5940
• Fax: N/A
• Employees: 250
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $9.93
• High Stock Price Target: $16.00
• Low Stock Price Target: $7.00
• Potential Upside/Downside: +45.4%
• Consensus Rating: Hold
• Rating Score (0-4): 2.29
• Research Coverage: 7 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.90)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-49,530,000.00
• Net Margins: -30.33%
• Pretax Margin: -30.33%
• Return on Equity: -51.12%
• Return on Assets: -26.36%

Debt

• Debt-to-Equity Ratio: 0.51
• Current Ratio: 4.12
• Quick Ratio: 2.98

Sales & Book Value

• Annual Sales: $209.36 million
• Price / Sales: 2.05
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.24 per share
• Price / Book: 3.05

Miscellaneous

• Outstanding Shares: 62,890,000
• Free Float: 47,078,000
• Market Cap: $429.54 million
• Optionable: Optionable
• Beta: 0.79